Work

Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.e14588

Authors: Hirva Mamdani, Jeffrey Melson Clarke, Lin Gu, Tom Stinchcombe, Jeffrey Crawford, Scott Joseph Antonia, Michael Campa, Andrew B. Nixon, Guru P. Sonpavde, George R. Simon, Neal E. Ready, JAMES E HERNDON, Edward F. Patz

Institutions: Wayne State University, The Barbara Ann Karmanos Cancer Institute, Duke University, Duke Medical Center, Duke Cancer Institute, AdventHealth Orlando, AdventHealth, Moffitt Cancer Center

Language: English

Topic: Complement system in diseases

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4399325149

Cites:

Cited by: 3

Related to: 10